The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LUMINOSITY, a phase 2 study of telisotuzumab vedotin in patients with c-Met protein–overexpressing non-squamous EGFR-wildtype advanced NSCLC: Efficacy outcomes by prior therapy.
 
Jonathan Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Summit Biomedical
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Pfizer (Inst); Summit Biomedical (Inst)
 
Shun Lu
Leadership - Innovent BIOLOGICS, INC; Shanghai Fosun; Simcere Zaiming
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Jair Bar
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Janssen Oncology; Medison; Merck Serono; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Immunai (Inst); MSD (Inst); Novartis (Inst); Oncohost (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Hidehito Horinouchi
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; BlossomHill Therapeutics, Inc.; Chugai Pharma; Daiichi Sankyo; Genmab; Novocure; Seagen; Yuhan
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BlossomHill Therapeutics, Inc. (Inst); BMKK (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Aaron Mansfield
Honoraria - Roche
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genzyme (Inst); Gilead Sciences (Inst); Janssen (Inst); Johnson & Johnson Global Services (Inst); Takeda (Inst)
Speakers' Bureau - Chugai/Roche (Inst)
Research Funding - Bristol Myers Squibb (Inst); Novartis (Inst); Verily (Inst)
Travel, Accommodations, Expenses - Abbvie; Roche
Other Relationship - Mesothelioma Applied Research Foundation
 
Christina Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen; Natera; Pfizer; Regeneron; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); TP Therapeutics (Inst)
 
John Hrom
No Relationships to Disclose
 
Rebecca Heist
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Biohaven Pharmaceuticals; Claim Therapeutics; Daichii Sankyo; Daichii Sankyo; Genentech/Roche; Gilead Sciences; Lilly; Merck; Novartis; Regeneron; Sanofi
Research Funding - Abbvie (Inst); Agios (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Modex (Inst); Mythic Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Christine Ratajczak
Employment - Abbvie
Stock and Other Ownership Interests - AbbVie
 
Shilpen Patel
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Deise Uema
Employment - Abbvie; Bayer; Daiichi Sankyo Inc
 
Summer Xia
Employment - Abbvie; Lilly
Stock and Other Ownership Interests - Abbvie; Lilly
Travel, Accommodations, Expenses - Abbvie
 
Pallavi Mhaske
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Mukesh Verma
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
David Camidge
Honoraria - Abbvie; Apollomics; AstraZeneca; Daiichi Sankyo; Janssen; Kestrel Labs; Lilly; Nuvalent, Inc.; Roche; takeda
Research Funding - Inivata (Inst)